CAGR oncology biomarker clinical trials by cancer type worldwide 2000-2018

This statistic depicts the compound annual growth rate (CAGR) of oncology biomarker clinical trials started worldwide between 2000 and 2018, by cancer type. During these years, brain/glioma/CNS cancer clinical trials had the highest CAGR of 25.1 percent, followed closely by lung cancer clinical trials with a CAGR of 24.9 percent.

CAGR of oncology biomarker clinical trials worldwide from 2000 to 2018, by cancer type*

Type of cancer	Compound annual growth rate (2000-2018)
Brain/glioma/CNS	25.1%
Lung	24.9%
Stomach	24.3%
Head and neck	23%
Melanoma	22.4%
Renal	21.6%
Potential pan-tumor**	21.2%
Colorectal	21.1%
Ovarian	19%
Myeloma	15.8%
Breast	14%
Pancreatic	13%
Lymphoma	12.6%
Leukemia	12.4%
Prostate	11.4%
Myelodysplastic syndromes (MDS)	11.2%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

November 2019

More information

Region

Worldwide

Survey time period

2000 to 2018

Supplementary notes

* Trials looking at two or more indications are repeat counted for each indication.
** Potential pan-tumor biomarker trials were determined based on a proxy of trial activity that could potentially lead to a pan-tumor label and included oncology biomarker clinical trials in Phase 2,3 or 4 with >five specified tumors per trial or

Citation formats